Abstract: The present invention relates to the sodium salt of (Z)-2-hydroxy-5-([4-[3-[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl ]-1-piperidinyl]-3-oxo-1-phenyl-1-propenyl]phenyl]azo]benzoic acid, as well as to the pharmaceutical compositions containing it, to a procedure for its preparation and to its use for the manufacture of medicaments for the treatment or prevention of inflammatory bowel disease.

Abstract: The present invention relates to the sodium salt of (Z)-2-hydroxy-5-[[4-[3-[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-piperidinyl]-3-oxo-1-phenyl-1-propenyl]phenyl]azo]benzoic acid, as well as to the pharmaceutical compositions containing it, to a procedure for its preparation and to its use. for the manufacture of medicaments for the treatment or prevention of inflammatory bowel disease.

Abstract: Neurodegenerative diseases, such as dementia, including Alzheimer's disease, can be treated or prevented by administering an effective amount of triflusal or its metabolite, or a pharmaceutically acceptable salt or a prodrug thereof.

Abstract: Neurodegenerative diseases, such as dementia, including Alzheimer's disease, can be treated or prevented by administering an effective amount of triflusal or its metabolite, or a pharmaceutically acceptable salt or a prodrug thereof.

Abstract: A method for inhibiting the activation of transcription factor NF-&kgr;B in a warm-blooded animal in need thereof, comprises administering to said animal an effective amount of a compound of formula I wherein R represents hydrogen or COCH3, or a pharmaceutically acceptable salt or a prodrug thereof.

Abstract: The invention relates to the use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-&kgr;B. The invention also relates to the utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives for the preparation of medicaments to treat or prevent of pathologies associated to the activation of NF-&kgr;B and/or the expression of genes which are dependent on or regulated by, at least partially, NF&kgr;B in mammals, including humans.

Abstract: An applicator for semi-solid medications comprises a tubular body (20) having a rounded dispensing end (21) provided with at least one opening (26) and a grasping end (22), the inner surface of a proximal portion of said tubular body defining a reservoir for the medication, a plunger (30), initially housed inside the tubular body, which plunger is provided with a rod (31) and grasping means (33), a piston (40), positioned in sealing contact with the inner surface of said tubular body providing a closure for the medication reservoir, wherein said piston has a longitudinal hole (45) through which rod (31) of the plunger is disposed, and wherein said piston initially abuts on a stop means (25) when the applicator is received by the user, a coupling means (35, 46) between rod (31) and piston (40), a closure means for sealingly closing off said opening (26) on said dispensing end, wherein the plunger (30) is extractable from the tubular body until the rod (31) becomes engaged with the piston (40) by the coupling m

Abstract: Compounds of formula I and their salts and solvates are useful for the treatment or prevention of inflammatory bowel disease. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.

Abstract: The present invention relates to 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine, to a process for its preparation and to pharmaceutical compositions containing it. This compound is a dual PAF antagonist and antihistamine.

Abstract: The present invention relates to 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro- 5H-benzo[5,6]cyclohepta[1,2-b]pyridine, to a process for its preparation and to pharmaceutical compositions containing it. This compound is a dual PAF antagonist and antihistamine.